Circulating dipeptidyl peptidase 3 (cDPP3) is a protease involved in the degradation of angiotensin II which disturbs peripheral blood pressure regulation and compromises left ventricular function. A new study by Florian A. Wenzl et al. published in the European Heart Journal identified cDPP3 as a novel marker of cardiogenic shock (CS) and increased mortality in patients with (ACS).

Circulating levels of acetylcarnitine independently predict residual cardiovascular risk in patients with ACS.

Read full article (European Heart Journal, 41, 2, 2020)

New Frontiers in Cardiovascular Medicine E-book on the Implications of lipids and modified lipoproteins in atherogenesis: From mechanisms towards novel diagnostic and therapeutic targets. Check it out here!

Enhancing SIRT1 activity exerts beneficial cardiovascular effects. In diabetes, plasma SIRT1 levels are reduced.

Read full article (Cardiovascular Research (2023) 00, 1–12)

In collaboration with the Medical University of Vienna and the University Hospital of Zurich, members of the Center for Molecular Cardiology have studied the role of growth differentiation factor-15 (GDF-15) for its predictive utility for adverse events in patients with cancer.

Access the full article

Identifying the IRA in patients with ACSs has profound diagnostic, therapeutic, and prognostic implications

Read full article (Eur Heart J Qual Care Clin Outcomes (2023) 0, 1–11)

Low-density lipoprotein (LDL)-cholesterol (LDL-C) promotes atherosclerotic cardiovascular disease (ASCVD), with changes in LDL electronegativity modulating its pro-atherogenic/pro-thrombotic effects.

Read full article (Atherosclerosis 376 (2023) 43–52)

Das Leben besteht aus mehr als nur Arbeit, auch für engagierte Kardiolog:innen, Gastroenterolog:innen und Ernährungsmediziner:innen. So geniessen wir alle – und auch die Patient:innen – gerne Wein, Getränke, Süssigkeiten und Kaffee, allein oder in Gesellschaft. Sind das verbotene Freuden oder schützen sie gar vor Krankheit und Tod?

Lesen Sie den ganzen Artikel (gastroMAG, N°2, Mai 2023)

For many years, cardiovascular disease was considered a male disease. Consequently, common data of registries, clinical trials and the like, were all reported for the entire patient population and only until recently has it become mandatory to report data on males and females separately.

Read full article (Cardiovasc Med 2023;26(3):67)

Cardiovascular (CV) diseases remain the leading cause of death globally, of which the majority are due to chronic and acute coronary syndromes (ACS).

Read full article (European Heart Journal: Acute Cardiovascular Care (2023) 00, 1–14)